Wugen, Inc.
Clinical trials sponsored by Wugen, Inc., explained in plain language.
-
Experimental CAR-T therapy targets tough blood cancers in early trial
Disease control CompletedThis early-phase study tested a new treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that came back or didn't respond to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New immune therapy shows promise in early leukemia trial
Disease control CompletedThis early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The goal was to check safety and find the best dose. Participants received immune cells designed to attack cancer. Thi…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC